EUVIMED · CrossrefJournal
Drug Discovery Today
ISSN 1359-6446 · Elsevier BV
Latest articles
Does Australia’s Reformed R&D Tax Incentive Scheme Spur or Stifle Innovation?
First Approval of Semaglutide for MASH in India: A Paradigm Shift in MASLD Management?
From chemical space to synthetic reality: A framework for makeable-by-design generative AI in drug discovery
Synthetic lethality and context-selective DNA-damage response dependencies: from genetic vulnerability to pharmacological translation
Pathway-driven target prioritisation in drug discovery
Chemoproteomics in covalent cancer drug discovery
New insights into FOX proteins in cancer
Advancing a drug-development program is not the same as de-risking it
From artificial intelligence promise to translational practice in drug discovery: Reproducibility, validation and evidence-based implementation
AI-integrated iPSC multi-omics: advancing phenotype discovery and drug target identification in rare diseases
NR4A2: a next-generation drug target orchestrating dynamic gene regulation and protein interactions
Methadone: Historical success, modern challenges and lessons for opioid drug discovery
Aptamer-based therapeutics for malaria and neglected tropical diseases
Advancing interleukin druggability: beyond ligandability toward therapeutic efficacy
Incretin and nutrient-sensing GPCR therapeutics in type 2 diabetes: What target–modality–formulation matching explains
PARP-1 selective inhibitors: A new direction in drug discovery to improve the therapeutic index of PARP-targeted cancer therapy
Networked innovation in the new modality era: strategic insights from spin-offs and precision medicine
Target-state uncertainty in drug discovery: when precise binding data describe the wrong system
The Activity Wall in Alzheimer’s drug discovery: When potency optimization reaches its limits
Medicine’s missing memory: what AI’s mathematical breakthrough reveals about biomedicine
Programmable STING-activating hydrogels for in situ cancer vaccination: Spatiotemporal design and mechanistic evidence
Everything is local: a framework for clinical global assessment in drug development
Harnessing exosomes for breast cancer: bridging conceptual promise to tangible translational application
Rational design and research progress of novel mitochondrial uncouplers
Exploring the unexplored without losing sight of the evidence: artificial data in drug discovery
Discovery, design, and applications of environment-responsive antibodies
Targeted protein degradation as a resistance-resilient strategy for antiviral drug discovery
Crosstalk between the cell cycle and ferroptosis in tumor cells
UHRF1-mediated epigenetic dysregulation in tumors: Mechanisms, therapeutic resistance and targeted inhibitors
Tumor hypoxia: Molecular pathways and therapeutic interventions
Volumes
2026 · 3012025 · 2682024 · 2792023 · 3002022 · 3022021 · 3042020 · 2752019 · 2852018 · 2412017 · 2172016 · 2342015 · 2042014 · 2812013 · 1852012 · 1972011 · 1742010 · 2542009 · 1792008 · 1772007 · 1752006 · 1812005 · 3632004 · 3552003 · 3592002 · 4432001 · 4502000 · 1861999 · 1401998 · 1481997 · 1411996 · 230
EUVIMED